News + Filings Transactions
|
BUTITTA CYNTHIA M
| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 06/27/2023 | Century Therapeutics, Inc. | | Grant | Stock Option (right to buy) | 44k | $3.19 | $140.4k | | 06/27/2023 |
| 06/17/2022 | Olema Pharmaceuticals, Inc. | OLMA | Grant | Stock Option (right to buy) | 21.5k | $0.00 | $0 | | 06/17/2022 |
| 06/16/2022 | Olema Pharmaceuticals, Inc. | OLMA | Grant | Stock Option (right to buy) | 21.5k | $3.43 | $73.8k | | 06/16/2022 |
| 06/09/2022 | Century Therapeutics, Inc. | | Grant | Stock Option (right to buy) | 19.9k | $8.56 | $170.1k | | 06/09/2022 |
| 06/08/2022 | UroGen Pharma Ltd. | URGN | Grant | Stock Option (right to buy) | 10k | $7.06 | $70.6k | | 06/08/2022 |
| 06/17/2021 | Century Therapeutics, Inc. | | Grant | Option (right to buy) | 19.9k | $20.00 | $397.4k | | 06/17/2021 |
| 06/09/2021 | Olema Pharmaceuticals, Inc. | OLMA | Grant | Stock Option (right to buy) | 21.5k | $27.66 | $595.2k | | 06/09/2021 |
| 06/07/2021 | UroGen Pharma Ltd. | URGN | Grant | Stock Option (right to buy) | 10k | $17.98 | $179.8k | | 06/07/2021 |
| 11/18/2020 | Olema Pharmaceuticals, Inc. | OLMA | Grant | Stock Option (Right to Buy) | 21.5k | $19.00 | $408.9k | | 08/12/2020 |
| 09/16/2020 | Olema Pharmaceuticals, Inc. | OLMA | Exercise | Stock Option (Right to Buy) | 83.9k | $4.41 | $369.6k | | 08/12/2020 |
| 08/12/2020 | Olema Pharmaceuticals, Inc. | OLMA | Grant | Stock Option (Right to Buy) | 83.9k | $4.41 | $369.6k | | 08/12/2020 |
| 06/08/2020 | UroGen Pharma Ltd. | URGN | Grant | Stock Option (right to buy) | 10k | $28.24 | $282.4k | | 06/08/2020 |
| 06/03/2019 | UroGen Pharma Ltd. | URGN | Grant | Stock Option (Right to Buy) | 10k | $34.83 | $348.3k | | 06/03/2019 |
| 09/25/2017 | Kite Pharma, Inc. | KITE | Sale | Common Stock | 4.2k | $179.66 | $759.6k | | 09/25/2017 |
| 09/25/2017 | Kite Pharma, Inc. | KITE | Grant | Common Stock | 8k | $0.00 | $0 | | 09/25/2017 |
| 08/10/2017 | Kite Pharma, Inc. | KITE | Sale | Common Stock | 5.8k | $121.03 | $702k | | 08/10/2017 |
| 08/10/2017 | Kite Pharma, Inc. | KITE | Sale | Common Stock | 9.2k | $120.52 | $1.1M | | 08/10/2017 |
| 08/10/2017 | Kite Pharma, Inc. | KITE | Exercise | Employee Stock Option (Right to Buy) | 15k | $1.35 | $20.2k | | 08/10/2017 |
| 07/10/2017 | Kite Pharma, Inc. | KITE | Sale | Common Stock | 3.3k | $101.06 | $338.2k | | 07/10/2017 |
| 07/10/2017 | Kite Pharma, Inc. | KITE | Sale | Common Stock | 5.6k | $102.19 | $567.5k | | 07/10/2017 |
| 07/10/2017 | Kite Pharma, Inc. | KITE | Sale | Common Stock | 1.1k | $102.81 | $113.1k | | 07/10/2017 |
| 07/10/2017 | Kite Pharma, Inc. | KITE | Sale | Common Stock | 5k | $105.50 | $527.5k | | 07/10/2017 |
| 07/10/2017 | Kite Pharma, Inc. | KITE | Exercise | Employee Stock Option (Right to Buy) | 15k | $1.35 | $20.2k | | 07/10/2017 |
| 06/23/2017 | Kite Pharma, Inc. | KITE | Sale | | 3k | $100.54 | $296.6k | | 06/23/2017 |
| 06/23/2017 | Kite Pharma, Inc. | KITE | Sale | | 2k | $101.19 | $207.4k | | 06/23/2017 |
| 06/23/2017 | Kite Pharma, Inc. | KITE | Exercise | | 5k | $1.35 | $6.8k | | 06/23/2017 |
| 06/23/2017 | Kite Pharma, Inc. | KITE | Sale | Common Stock | 2k | $101.19 | $207.4k | | 06/23/2017 |
| 06/23/2017 | Kite Pharma, Inc. | KITE | Sale | Common Stock | 3k | $100.54 | $296.6k | | 06/23/2017 |
| 06/09/2017 | Kite Pharma, Inc. | KITE | Exercise | Employee Stock Option (Right to Buy) | 10k | $1.35 | $13.5k | | 06/09/2017 |
| 06/09/2017 | Kite Pharma, Inc. | KITE | Sale | Common Stock | 400 | $84.81 | $33.9k | | 06/09/2017 |
| 06/09/2017 | Kite Pharma, Inc. | KITE | Sale | Common Stock | 900 | $86.42 | $77.8k | | 06/09/2017 |
| 06/09/2017 | Kite Pharma, Inc. | KITE | Sale | Common Stock | 2.5k | $87.80 | $219.7k | | 06/09/2017 |
| 06/09/2017 | Kite Pharma, Inc. | KITE | Sale | Common Stock | 4.1k | $89.09 | $365.3k | | 06/09/2017 |
| 06/09/2017 | Kite Pharma, Inc. | KITE | Sale | Common Stock | 1.7k | $89.76 | $152.4k | | 06/09/2017 |
| 06/09/2017 | Kite Pharma, Inc. | KITE | Sale | Common Stock | 400 | $91.08 | $36.4k | | 06/09/2017 |
|
|